FDA approved Aduhelm earlier this month, despite advisory committee's conclusion that there was not enough evidence to support its effectiveness

At day 15, significantly greater reduction seen in depressive symptoms as measured by change in HAMD-17 score from baseline

Gray market care, from an unregulated agency, often supplements unpaid or family care

53.0 percent in public health departments reported symptoms of at least one condition in survey conducted during March, April 2021

The company did not admit to any liability or wrongdoing in the settlement

50 percent of patients hospitalized with COVID-19 and 19 percent of asymptomatic patients had at least one post-COVID-19 condition

Increased in-hospital mortality for COVID-19 patients with schizophrenia versus those without severe mental illness

However, opioids still commonly dispensed, with high-risk prescribing practices suspected in young children

Wide variation seen in continuity of nursing staff for home health care visits to dementia patients following hospitalization

Donanemab has already received a 'breakthrough therapy' designation from the FDA